Following the successful cloning of the EPO gene in 1985 [4], human recombinant erythropoietin (rHuEPO) was developed and has been available in Japan for dialysis patients since 1990 and for patients with chronic renal failure since 1994, providing outstanding outcomes. This evidence concerns the gene EPO and chronic kidney disease.